CQP(000950)2025-01-10 16:00Financial Performance Forecast - The estimated net profit attributable to shareholders for 2024 is projected to be between 29,000 million and 39,000 million CNY, a decrease of 40.45% to 55.72% compared to the previous year's profit of 65,495.69 million CNY[2] - The estimated net profit after deducting non-recurring gains and losses is projected to be between 24,000 million and 32,000 million CNY, a decrease of 45.07% to 58.80% compared to the previous year's profit of 58,256.66 million CNY[2] - The basic earnings per share is expected to be between 0.17 CNY and 0.23 CNY, down from 0.38 CNY in the previous year[2] Factors Affecting Profitability - The decline in performance is primarily attributed to the expansion of centralized procurement policies, which have led to price adjustments for drugs and medical devices, impacting profitability[4] - Extended accounts receivable periods have resulted in increased impairment losses based on expected credit loss rates, further reducing profits[5] Financial Reporting and Risks - The financial data in this earnings forecast has not been audited by registered accountants[3] - The specific financial data will be detailed in the company's 2024 annual report, and investors are advised to pay attention to investment risks[6]